Mobile website
Translational Medicine
Current status of bench-to-bedside translation of the new immunomodulatory drug pomalidomide in treating malignancies
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Pomalidomide is a highly potent third-generation immunomodulatory drug (IMiD), with pharmacologic properties similar to those of the first-generation drug thalidomide. However, compared with thalidomide, pomalidomide has stronger antiangiogenic, antineoplastic, and anti-inflammatory, and anti-myeloma activities in vitro and in vivo, with less side effects and better oral tolerance. In February, 2013, pomalidomide has been approved by the U.S. Food and Drug Administration for use in the treatment of relapsed and refractory multiple myeloma (MM). This review will focus on the recent advances on the translation of pomalidomide from bench to bedside as a therapeutic agent for relapsed and refractory multiple myeloma, myelofibrosis, immunoglobulin light-chain amyloidosis (AL), small cell lung cancer (SCLC), and other advanced solid tumors.
Keywords:
Project Supported:
Clc Number:
